Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Misiu,
Our prayers are with you and your son.
LeronLimab to the rescue.
Best of Luck,
Leo
Critical Trial in Brazil is already approved!
https://www.reddit.com/r/LeronLimab_Times/comments/ozys0j/clarification_on_brazil_trials/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
Brazil Trials: Ethics approved for all trial sites
https://www.reddit.com/r/LeronLimab_Times/comments/ozys0j/clarification_on_brazil_trials/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
LOL! It wasn’t too difficult to take that out of Yo!
Now we all know what 13D is up to:
“Take over and liquidate Cytodyn”!
That ain’t gonna happen.
Justda, you are very diligent!
Could you point out where in the PR it said “expect to release results in mid-January 2021”?!
C-20, sincere condolences to you and your friend’s family.
May his soul Rest In Peace.
I urge you to share your earth shattering Cytodyn statistical model, and your 50+ references so we can all educate ourselves.
Or wait, maybe you are not a real statistician who always fails to provide any material reference for his/her claims!
Maybe you are someone like Robert M. Kowalsky from a failed Chicago Bank with at least $66M in nonperforming loans who is trying to fill up another big hole by pushing the naked short agenda on CYDY.
https://www.justice.gov/usao-ndil/pr/federal-criminal-probe-failure-chicago-bank-adds-new-charges-and-four-former-employees
I am afraid I don’t have good news for you as there are no shares available to short and CYDY is going to skyrocket any day now and leave the shorts bankrupt!
Mic Drop,
Leo
I have to agree with Justda that the subject was worthless in the 90’s.
But, but, but, we are living in 2021 now!
In the middle of a pandemic plagued by a “lab synthesized virus”. And there is only one drug, I repeat, “only one drug” from the 90’s with “primary end point of mortality reduction” that has passed the scrutiny of DSMC and finished the phase 3 trial with no change, I repeat “absolutely no change” to the end point, nor trial size, nor any change since the trial started; Has received FDA approval for open-label extension and eIND post phase 3 completion.
This worthless 90’s drug is called the one and only “LeronLimab” which is set to become the standard of care for COVID.
And just in time, there are people in charge who believe in science and will push it forward.
Mic Drop!
Leo
This post must be pinned!
I can’t wait for “ LeronLimab to be sworn in as the SoC for COVID”... Don’t Blink
Smiley, this is a dead serious account!There is legal precedent to subpoena for discovery under these circumstances... Take a look here:
SEC takes action against short seller for alleged securities fraud:
https://www.dlapiper.com/en/us/insights/publications/2018/10/sec-fires-warning-shot-against/
Fill in the blank with CYDY!
Whataboutdat?
What makes you assume all the hospitalized patients fall in the S/C category?!
There is no “instead of”!
All the agenda including FOIA and Naked Short investigations, and CD12 data analysis will be pushed forward! and NASDAQ Too!
Whataboutdat?
PMWC Virtual - 21st Century Precision Medicine in the Age of COVID-19
https://www.pmwcintl.com/covid/
Day 2 (January 26): COVID-19 Emerging Therapeutics, Vaccine Development & Diagnostics
11:30 AM (PST)
Development of New SARS-CoV-2 Therapeutics
The COVID-19 pandemic is driving unprecedented transformation of the global medical research ecosystem through the search for effective new therapeutics that can help ease symptoms and prevent death among COVID-19 patients.
I won’t forget about Dec. 22 either!!!
FDA Guidelines for NASH Drug development: https://www.fda.gov/media/127738/download?utm_medium=email&utm_source=govdelivery
FDA Webinar on Regulatory Perspectives for Development of Drugs for Treatment of NASH, Jan. 29, 2021:
https://www.fda.gov/drugs/news-events-human-drugs/regulatory-perspectives-development-drugs-treatment-nash-01292021-01292021?utm_medium=email&utm_source=govdelivery
Brian Barr: Investment Management
http://linkedin.com/in/brian-barr-12083936
Rock,
Any idea what % of COVID ICU patients in average may fall in the S/C (CD12) category?
Any of MD’s in the board: Do you know what % of COVID ICU patients in average fall in the category of S/C (CD12)?
Smart Move.
British Columbia rejects Bamlanivimab:
https://www.pharmaceutical-technology.com/news/british-columbia-rejects-bamlanivimab/
If CD12 results are not there, why would FDA approve open label extension and resume eIND?!!!
IMHO, FDA would merely make such a BOLD move only if they have strong confidence on the efficacy of the trial data which was provided to them by DSMC at 50% milestone, period!
The rest to me is all noise!
Let’s set the expectations right!
We have seen a strong resistance at $6 and the $7.
I don’t expect the SP to break the $6 before any positive news is out.
However, there is a long list of possible Positive news can leave the $6-$10 in the dust!
CD12 unblind on or around 1/12: it will take a min of 1-2wks to get the results out.
Nasdaq up-list: any time!
Philippines EUA: very likely aligned with CD12 top line.
Long Hauler trial: start to finish within days coming any time!
Interesting Data on S/C study group:
https://www.thelancet.com/article/S0140-6736(20)30633-4/fulltext
Study Size: 191
Total Death: 54
Overall Mortality Rate: 28%
If we apply 28% to 390/3=130, the mortality in the control group comes to ~36.4!
Note: mortality among patients requiring mechanical ventilation: 31 out of 32, i.e. 97%!!!
Thomas Landstreet on Cytodyn:
Emerging Growth Article on Cytodyn:
https://emerginggrowth.com/cytodyn-update-reveals-q1-sales-pipeline-philippine-eua-nasdaq-uplisting-high-likelihood-of-approval/
On 1/4 when the market was down 5%, CYDY closed 10% up!
With all the shorts, right now we are merely at the open SP of 1/4.
“SP falling rapidly” Debunked!
It sounds like Nader has a new guardian!
I bet you will be standing at the gate to stop Nader boarding the flight!
To echo that, The pain of taking my father to hospital and helplessly getting his cold body back within a couple of days still haunts me!
This is part of a conversation I had with Dr. Patterson on July 20, last year:
PL: Given the mutation cycle of COVID, which one do you think will be more effective: a vaccine or LeronLimab?
BP: LeronLimab
Justa,
Looks like you missed my question.
“Do you have any scientific or statistical evidence to support your claim that CD12 is a flop?”
Justda,
CFO and other insiders selling and buying shares is a fact. However, it is not a scientific or statistical evidence on the outcome of CD12.
CD12 clinical trial was reviewed by DSMC at 50% patient registration milestone and was recommended to continue the trial with no modification:
https://www.google.com/amp/s/www.nasdaq.com/articles/cytodyn%253A-dsmc-recommends-to-continue-leronlimab-covid-19-registrational-trial-2020-10-20%3Famp
Long-Hauler Start Date Updated: Jan. 21, 2021.
https://clinicaltrials.gov/ct2/show/NCT04678830?term=Leronlimab&draw=2&rank=7
Justda,
Thanks for sharing your thoughts.
Do you have a scientific or statistical evidence that makes you believe CD12 will be a flop?
I’m sure everyone on this board loves to review your thoughts and evidence on this claim.
Why tomorrow’s CC is different from the past?!
Because none of the updates are going to affect the most anticipated CD12 unblind and top line report date and outcome!
The rest is icing on the cake, or maybe a multi-tier cake!!!
IMO!
Respect CT!
This post is a school of dialogue!
When CYDY takes off, people will be hitting themselves that how fool did they not buy it so cheap at $6.50 or lower!!!
B’Ops, This post is priceless!
I have converted all my AAPL to CYDY.
Time will judge the outcome as you say.
B’Ops!
Love that vision board.
Amen!